Atossa Genetics, Inc. (ATOS) Starts Presentation at 2nd Annual Marcum MicroCap Conference
Atossa Genetics, The Breast Health Company™, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography. Atossa markets ForeCYTE Breast Health Test and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors. For more information visit the company’s Web site at www.atossagenetics.com
Let us hear your thoughts below:
The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in
Marcum MicroCap. Bookmark the
permalink.
